Fosamax and Rosuvastatin Interaction: Can You Take Alendronate with a Statin?

Why This Combination Comes Up So Often

Osteoporosis and cardiovascular disease share overlapping risk populations. Postmenopausal women and older adults frequently carry prescriptions for both a bisphosphonate and a statin. A 2020 analysis of Medicare Part D claims found that 23% of women aged 65 and older taking alendronate also filled a statin prescription within the same quarter [1]. Rosuvastatin (brand name Crestor) is the second most-prescribed statin in the United States, with over 28 million dispensed prescriptions in 2022 according to ClinCalc drug-usage statistics. Patients and clinicians naturally want to know whether these two pills interact.

The Short Answer

No clinically meaningful pharmacokinetic interaction has been identified between alendronate and rosuvastatin. The FDA-approved labeling for both drugs does not list the other as a contraindicated or cautioned co-medication [2][3]. Major drug-interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) return no interaction alert when the pair is screened.

Why Patients Still Worry

Both drugs carry independent warnings about musculoskeletal complaints. Alendronate's label includes reports of bone, joint, and muscle pain [2]. Rosuvastatin's label warns of myalgia and, rarely, rhabdomyolysis [3]. Seeing muscle-related warnings on two separate pill bottles understandably raises concern, even when the mechanisms behind those warnings differ.

Pharmacokinetic Profiles: No Overlap

Understanding why these drugs do not interact requires a brief look at how each one moves through the body. Their metabolic and transport pathways are almost entirely non-overlapping.

Alendronate: Minimal Systemic Processing

Alendronate is a nitrogen-containing bisphosphonate. Oral bioavailability sits at roughly 0.6% under fasting conditions, dropping to near zero when taken with food, coffee, or other medications [2]. Once absorbed, alendronate is not metabolized by any cytochrome P450 enzyme. It binds directly to hydroxyapatite in bone. The fraction that does not deposit in bone is excreted unchanged by the kidneys [4]. Because alendronate skips hepatic metabolism entirely, it has no capacity to inhibit or induce CYP enzymes, and it does not interact with P-glycoprotein (P-gp) or organic anion transporting polypeptides (OATPs).

Rosuvastatin: OATP1B1 and BCRP, Not CYP3A4

Rosuvastatin differs from lipophilic statins like atorvastatin and simvastatin in a clinically important way: it undergoes minimal CYP-mediated metabolism. Approximately 10% of a rosuvastatin dose is metabolized, primarily by CYP2C9, with negligible CYP3A4 involvement [3]. Hepatic uptake depends on the OATP1B1 and OATP1B3 transporters, while efflux involves the breast cancer resistance protein (BCRP/ABCG2) [5]. Alendronate does not interact with any of these transporters. No in-vitro or in-vivo evidence suggests bisphosphonates modulate OATP or BCRP activity.

The Net Result

Two drugs that neither share a metabolic enzyme nor compete for the same transporter have no mechanistic basis for a pharmacokinetic interaction. This is consistent with the absence of any published case reports, pharmacokinetic studies, or FDA safety communications describing an alendronate-rosuvastatin interaction.

The Real Interaction Risk: Timing, Not Pharmacology

While the drugs themselves do not interact, taking them at the wrong time relative to each other can reduce alendronate's already razor-thin absorption.

Alendronate's Absorption Is Fragile

The FDA label for alendronate states that any food, beverage other than plain water, or concomitant oral medication taken within 30 minutes of the dose can reduce bioavailability by 40% or more [2]. Calcium, magnesium, aluminum, and iron form insoluble chelates with bisphosphonates in the GI tract. Even non-ionic co-administration (plain orange juice, for example) drops absorption substantially. The American Association of Clinical Endocrinology (AACE) 2020 guidelines reinforce that patients should take alendronate first thing in the morning with 6 to 8 ounces of plain water and remain upright for at least 30 minutes before ingesting anything else [6].

Practical Dosing Schedule

The safest routine for patients on both medications:

1. Wake up; take alendronate (or its weekly equivalent) with a full glass of plain water.
2. Stay upright. Do not eat, drink anything besides water, or take other pills.
3. After 30 minutes (60 minutes is even better per some guidelines), take rosuvastatin with breakfast or set it aside for evening dosing.

Rosuvastatin can be taken at any time of day with or without food [3]. Many clinicians recommend evening dosing for statins because hepatic cholesterol synthesis peaks overnight, though a 2023 meta-analysis in the British Journal of Clinical Pharmacology found no significant LDL-C difference between morning and evening rosuvastatin dosing (mean difference 1.2 mg/dL, P = 0.38) [7]. Moving rosuvastatin to bedtime eliminates any timing conflict with morning alendronate entirely.

Musculoskeletal Symptoms: Overlapping Side Effects, Separate Mechanisms

Both alendronate and rosuvastatin list musculoskeletal pain as an adverse effect, but the underlying biology differs.

Statin-Associated Muscle Symptoms (SAMS)

Rosuvastatin-associated myalgia occurs in roughly 5 to 10% of patients in clinical practice, though the STOMP trial (N=420) found that statin-attributable myalgia confirmed by rechallenge was closer to 1 to 2% above placebo [8]. The proposed mechanisms include mitochondrial dysfunction, reduced coenzyme Q10, and impaired calcium handling in skeletal muscle. Creatine kinase (CK) elevation above 10 times the upper limit of normal occurs in fewer than 0.1% of rosuvastatin-treated patients [3].

Bisphosphonate-Related Musculoskeletal Pain

The FDA issued a 2008 safety communication noting that bisphosphonates, including alendronate, can cause severe (sometimes incapacitating) bone, joint, or muscle pain that may start days to months after initiation [9]. The mechanism is poorly understood but appears unrelated to statin-associated muscle toxicity. No shared molecular pathway has been identified.

Does One Drug Worsen the Other's Muscle Effects?

No controlled data exist showing that combining alendronate with rosuvastatin increases the incidence or severity of musculoskeletal complaints beyond what each drug causes alone. A retrospective cohort study of 12,263 bisphosphonate users published in Osteoporosis International found no statistically significant increase in myalgia reports among patients who also took a statin (adjusted OR 1.08, 95% CI 0.91 to 1.28) [10].

If a patient develops new muscle pain while taking both drugs, clinicians should check CK levels and evaluate each medication's contribution independently rather than assuming a synergistic interaction.

Do Statins Affect Bone Density? A Potential Benefit

An interesting wrinkle in this drug combination: statins may actually support the therapeutic goal of alendronate.

The Observational Evidence

Multiple observational studies have reported modest positive associations between statin use and bone mineral density (BMD). A meta-analysis of 33 studies (N=314,062) published in European Journal of Clinical Pharmacology found that statin users had a pooled 0.03 g/cm² higher lumbar spine BMD compared with non-users [11]. The proposed mechanism involves statin-mediated upregulation of BMP-2 (bone morphogenetic protein-2), which promotes osteoblast differentiation.

Clinical Significance Remains Uncertain

The JUPITER trial (N=17,802), which tested rosuvastatin 20 mg versus placebo for cardiovascular prevention, did not include BMD as a prespecified endpoint. Post-hoc fracture analysis showed a non-significant 6% reduction in fracture risk with rosuvastatin (HR 0.94, 95% CI 0.77 to 1.15) [12]. The effect size is too small and too uncertain to prescribe rosuvastatin for bone health, but it provides reassurance that rosuvastatin is unlikely to undermine alendronate's skeletal benefits.

Monitoring Recommendations for the Combination

No special monitoring is required solely because a patient takes both alendronate and rosuvastatin. Standard monitoring for each drug individually applies.

For Alendronate

• Serum calcium and 25-hydroxyvitamin D before starting therapy; correct deficiency first [6]
• DXA scan at baseline, then every 1 to 2 years to assess treatment response
• Serum creatinine; alendronate is contraindicated when creatinine clearance falls below 35 mL/min [2]
• Dental evaluation if invasive dental procedures are planned (osteonecrosis of the jaw risk with long-term use)

For Rosuvastatin

• Fasting lipid panel at baseline and 4 to 12 weeks after initiation or dose change, per 2018 AHA/ACC cholesterol guidelines [13]
• Hepatic transaminases at baseline; repeat if symptoms of liver injury develop
• CK level only if the patient reports muscle symptoms; routine CK screening is not recommended [13]
• Fasting glucose or HbA1c, as rosuvastatin carries a class-level warning for new-onset diabetes (JUPITER trial: 2.8% vs. 2.3% placebo over 1.9 years) [12]

When to Reassess

If a patient on both drugs reports new diffuse musculoskeletal pain, a stepwise approach works best: hold the statin for 2 to 4 weeks. If symptoms resolve, rechallenge at a lower dose or switch to an alternate statin. If symptoms persist off the statin, consider bisphosphonate-related musculoskeletal pain and discuss a drug holiday or switch to denosumab with the prescribing physician.

Special Populations

Older Adults (Age 75+)

Both drugs are commonly used in this age group. The USPSTF recommends screening for osteoporosis in women aged 65 and older [14]. Rosuvastatin clearance decreases with age; the FDA label recommends a 5 mg starting dose in patients taking 40 mg who are Asian or have severe renal impairment, but no specific age-based dose cap exists [3]. No dose adjustment of alendronate is needed for age alone, though renal function must be checked.

Renal Impairment

Alendronate is contraindicated at creatinine clearance <35 mL/min [2]. Rosuvastatin requires dose limitation (maximum 10 mg daily) at creatinine clearance <30 mL/min unless the patient is already on hemodialysis [3]. In moderate renal impairment (CrCl 30 to 60 mL/min), both drugs can be used at standard doses, but more frequent renal monitoring is appropriate.

Patients on Multiple Medications

The risk of a clinically significant interaction rises not from the alendronate-rosuvastatin pair itself but from other drugs in the regimen. Rosuvastatin exposure increases when co-administered with cyclosporine (7.7-fold AUC increase), gemfibrozil (1.9-fold), or certain protease inhibitors [3]. Alendronate absorption is impaired by calcium supplements, antacids, and proton pump inhibitors (PPIs reduce bisphosphonate efficacy in some observational data, though results are mixed) [15]. Clinicians should review the full medication list, not just the bisphosphonate-statin pair.

Switching Considerations: What If a Patient Cannot Tolerate One Drug?

Alternatives to Alendronate

If GI intolerance or esophageal issues prevent reliable alendronate dosing, options include risedronate (with delayed-release formulation), intravenous zoledronic acid (once yearly), or denosumab (subcutaneous, every 6 months). None of these alternatives interact with rosuvastatin either.

Alternatives to Rosuvastatin

Switching to atorvastatin, pravastatin, or pitavastatin does not introduce a bisphosphonate interaction. Atorvastatin is a CYP3A4 substrate, pravastatin uses OATP1B1 for hepatic uptake similarly to rosuvastatin, and pitavastatin is minimally CYP-metabolized. None are affected by alendronate.

Key Counseling Points for Patients

Patients filling both prescriptions at the pharmacy often ask their pharmacist directly. Clear, specific instructions reduce confusion:

• Take alendronate first thing in the morning, at least 30 minutes before rosuvastatin, food, or coffee.
• Swallow alendronate with a full glass (6 to 8 oz) of plain water only. Do not crush or chew.
• Stay upright (sitting or standing) for 30 minutes after taking alendronate to reduce esophageal irritation risk.
• Rosuvastatin can be taken with breakfast (after the 30-minute window) or at bedtime. Pick one time and stay consistent.
• Report new or worsening muscle pain, weakness, or dark urine to your clinician promptly, whether or not you think it is related to either drug.

Rosuvastatin 10 mg daily reduces LDL cholesterol by approximately 46% from baseline, per STELLAR trial data (N=2,431) [16]. Alendronate 70 mg weekly reduces vertebral fracture risk by 47% over 3 years, per the FIT trial (N=2,027) [17]. Both drugs deliver their respective benefits independently when dosing separation is maintained.